PLK1 inhibitors appear to be versatile anticancer agents for a variety of cancers, and their recent interplay with immunotherapies (Reda et al, 2022; Zhang et al, 2022) will likely open interesting research avenues for melanoma treatment. This evidence concerns the gene PLK1 and melanoma.